Skip to content

Certara

US · CERT #2994 by market cap Listed 2020
10.55 -0.13 -1.22%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Valuation each multiple against its own 5-year range

P/B ratio 1.80 In line with history 39th percentile
5-year average 2.23 · #18 of 37 in Health Information Services
P/E ratio -27.55 In line with history 64th percentile
5-year average -90.41 · forward -302.46
P/S ratio 4.15 Cheap vs history 21st percentile
5-year average 6.87 · forward 4.55 · #27 of 41 in Health Information Services

Vs. peers Health Information Services

Company Market cap P/E (TTM) P/B Div yield
Certara (CERT) 1.61B -25.12 1.65 0.00%
Veeva Systems (VEEV) 43.10B 43.64 5.80 0.00%
BrightSpring Health Services (BTSG) 12.50B 33.78 5.75 0.00%
Tempus AI (TEM) 9.86B -50.98 19.70 0.00%
Hinge Health (HNGE) 8.60B 51.68 28.71 0.00%
HealthEquity (HQY) 7.84B 34.21 3.94 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value12.99 Economic moatNone UncertaintyHigh

Trading 23.1% below Morningstar's fair value estimate.

Fair value

Certara Inc receives a 3-star quantitative star rating, indicating our belief that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 11% discount to our quantitative fair value estimate of $12.99 per share; however, caution is warranted due to this estimate's high uncertainty rating.

The firm's balance sheet increases our fair value estimate. Leverage can enable a company to invest in growth, potentially boosting shareholder value more than equity financing alone. Reflecting the firm's leverage is its EBITDA/interest coverage ratio of 4.3, which falls in the bottom 30% globally. Although the firm's ability to cover interest payments with EBITDA is limited, shares could sharply rebound if economic circumstances change or recent investments reduce fears of default. We believe this is a sign that shares could be cheap.

On a different note, the company's lack of profitability is potentially concerning. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's earnings yield of -0.4%, for example, lies in the bottom 30% compared with global peers. The earnings generated by the company relative to its share price is concerning, which, despite our favorable price/fair value ratio, is a negative attribute.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has been a laggard relative to the broader universe over the past year. This underperformance makes the stock appear cheap, which portends a buying opportunity in light of other contributors to our model.

Economic moat

This company lacks a competitive advantage, receiving a quantitative economic moat rating of none. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-11-20 20:02:24 · For reference only, not investment advice and not tailored to your situation.

Certara discussion 0 comments

Add a comment